MedPath

Evaluation of Visual Outcomes of Monovision Patients Bilaterally Implanted With Nanoflex Intraocular Lenses

Phase 4
Conditions
Patients Who Have Bilateral NanoFlex Implantation at Least 3 Months Previously
Interventions
Device: Nanoflex IOL
Registration Number
NCT01279122
Lead Sponsor
Innovative Medical
Brief Summary

The purpose of this study is to look at how well you see the Nanoflex Intraocular lens placed in your eye.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Male or female patients at least 18 years of age.
  • Patients who have bilateral NanoFlex implantation at least 3 months previously.
  • No significant ocular pathology causing DCVA to be less than 20/25 or causing significant visual loss.
  • DCVA of 20/25 or better in both eyes.
  • Spherical equivalent in the dominant eye to be +/-.50 or less and in the non-dominant eye to be between-1.00 and -1.87.
  • Uncorrected VA in dominant eye 20/25 or better.
Exclusion Criteria
  • History of ocular trauma or prior ocular surgery (minor ocular trauma is allowed such as small superficial corneal scar not effecting vision; some prior ocular surgery is allowable so long as it has not impacted visual acuity.
  • Amblyopia or strabismus, significant visual field loss, or posterior capsular opacifcation.
  • Known pathology that may affect visual acuity; particularly retinal changes that affect vision (macular degeneration, cystoid macular edema, proliferative diabetic retinopathy, etc.).

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Nanoflex IOLNanoflex IOL-
Primary Outcome Measures
NameTimeMethod
Uncorrected Near Visual Acuity1 year
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Kenneth Lipstock

🇺🇸

Richmond, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath